Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03008915 · ClinicalTrials.gov registry record · Phase 2
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03008915 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 15 participants.
The verdict
NCT03008915, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The aim of this study is to test whether aspirin improves endothelial function in alpha-1 antitrypsin deficiency-associated lung disease, measured by pulmonary microvascular blood flow on magnetic resonance imaging (MRI) and with apoptotic endothelial microparticles.
Interventions
- DRUG Placebo
- DRUG Aspirin
- OTHER Withdrawal from alpha1 antitrypsin replacement therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03008915
The ClinicalTrials.gov registry entry for NCT03008915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03008915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03008915 about?
NCT03008915 is a clinical study titled "Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency". The aim of this study is to test whether aspirin improves endothelial function in alpha-1 antitrypsin deficiency-associated lung disease, measured by pulmonary microvascular blood flow on magnetic resonance imaging (MRI) and with apoptotic endothelial microparticles.
What is the current status of trial NCT03008915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-01. Estimated completion is 2020-10.
What interventions are being tested in trial NCT03008915?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Withdrawal from alpha1 antitrypsin replacement therapy (OTHER).
Who is sponsoring clinical trial NCT03008915?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.